Euro DEHP RA (risk assessment) by June?
This article was originally published in Clinica
Executive Summary
The European Union's routine risk assessment of DEHP, the softener used in PVC medical devices, could be into its final stages by early June. That is when the next sitting of the quarterly "technical meeting on existing chemicals" is held, in Arona, Italy. Member state representatives attending the last meeting, in mid-March, requested more time to review new findings on toxicity in rats, by Schilling (2002), a two-generation study in rats, and those contained in a report presented to the US Society of Toxicology meeting in Nashville on March 20. EU member states have until April 19 to put forward their final position.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.